Serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide labels the 5-HT1D beta receptor subtype in human cortex.
This study, carried out in human cerebral cortical membranes, confirms previous findings in human substantia nigra that serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide ([125I]GTI) labels a homogeneous population of recognition sites consistent with a 5-HT1D receptor pharmacology. In addition the results indicate that, under the assay conditions described, [125I]GTI specifically labels the 5-HT1D beta recognition site since ketanserin and ritanserin display a low affinity consistent with their activities at this subtype of the 5-HT1D receptor.
Beer
M S
MS
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
Middlemiss
D N
DN
D002540:Cerebral Cortex / Q000378:metabolism*; D004151:Dipeptides / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D011869:Radioligand Assay; D011985:Receptors, Serotonin / Q000378:metabolism*; D012701:Serotonin / Q000031:analogs & derivatives* / Q000378:metabolism
D004151:Dipeptides; D007457:Iodine Radioisotopes; D011985:Receptors, Serotonin; C072128:serotonin-O-carboxymethyl-Gly-Tyr; D012701:Serotonin